---
title: Prognostic significance of immune reconstitution following CD19 CAR T-cell
  therapy for relapsed/refractory B-cell lymphoma
date: '2025-01-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39807276/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250114170947&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Immune deficits after CD19 chimeric antigen receptor (CAR) T-cell therapy
  can be long-lasting, predisposing patients to infections and non-relapse mortality.
  In B-cell non-Hodgkin lymphoma (B-NHL), the prognostic impact of immune reconstitution
  (IR) remains ill-defined, and detailed cross-product comparisons have not been performed
  to date. In this retrospective observational study, we longitudinally characterized
  lymphocyte subsets and immunoglobulin levels in 105 B-NHL patients to ...
disable_comments: true
---
Immune deficits after CD19 chimeric antigen receptor (CAR) T-cell therapy can be long-lasting, predisposing patients to infections and non-relapse mortality. In B-cell non-Hodgkin lymphoma (B-NHL), the prognostic impact of immune reconstitution (IR) remains ill-defined, and detailed cross-product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B-NHL patients to ...